Weining Robieson

2.5k total citations · 1 hit paper
62 papers, 1.7k citations indexed

About

Weining Robieson is a scholar working on Neurology, Psychiatry and Mental health and Epidemiology. According to data from OpenAlex, Weining Robieson has authored 62 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Neurology, 20 papers in Psychiatry and Mental health and 13 papers in Epidemiology. Recurrent topics in Weining Robieson's work include Parkinson's Disease Mechanisms and Treatments (27 papers), Neurological disorders and treatments (21 papers) and Restless Legs Syndrome Research (13 papers). Weining Robieson is often cited by papers focused on Parkinson's Disease Mechanisms and Treatments (27 papers), Neurological disorders and treatments (21 papers) and Restless Legs Syndrome Research (13 papers). Weining Robieson collaborates with scholars based in United States, United Kingdom and Italy. Weining Robieson's co-authors include Ahmed A. Othman, Yili Pritchett, David G. Standaert, Janet Benesh, Krai Chatamra, Robert Lenz, Angelo Antonini, Hubert H. Fernandez, Alberto J. Espay and Per Odin and has published in prestigious journals such as American Journal of Psychiatry, Neurology and The Lancet Neurology.

In The Last Decade

Weining Robieson

61 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study

2013 487 citations Alberto J. Espay, David G. Standaert et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Weining Robieson United States	22	1.0k	328	323	276	260	62	1.7k
Jae Woo Kim South Korea	20	899 0.9×	199 0.6×	203 0.6×	198 0.7×	168 0.6×	86	1.4k
Christine Hunter United States	26	1.4k 1.4×	271 0.8×	837 2.6×	98 0.4×	289 1.1×	68	2.2k
Christine Brefel‐Courbon France	23	1.5k 1.5×	199 0.6×	497 1.5×	149 0.5×	195 0.8×	59	2.2k
Rosanna Tortelli Italy	25	721 0.7×	271 0.8×	210 0.7×	80 0.3×	302 1.2×	64	1.6k
Monika Balzer‐Geldsetzer Germany	24	507 0.5×	235 0.7×	267 0.8×	88 0.3×	283 1.1×	56	1.7k
Peter Valkovič Slovakia	20	786 0.8×	255 0.8×	160 0.5×	168 0.6×	131 0.5×	78	1.3k
E. Dupont Denmark	24	1.4k 1.4×	185 0.6×	557 1.7×	137 0.5×	177 0.7×	66	2.0k
Naveed Malek United Kingdom	20	975 0.9×	230 0.7×	265 0.8×	96 0.3×	146 0.6×	48	1.4k
Ann‐Kathrine Granérus Sweden	20	892 0.9×	379 1.2×	194 0.6×	129 0.5×	162 0.6×	39	1.5k
Louis Tan Singapore	22	839 0.8×	197 0.6×	215 0.7×	124 0.4×	183 0.7×	44	1.3k

Countries citing papers authored by Weining Robieson

Since Specialization

Citations

This map shows the geographic impact of Weining Robieson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Weining Robieson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Weining Robieson more than expected).

Fields of papers citing papers by Weining Robieson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Weining Robieson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Weining Robieson. The network helps show where Weining Robieson may publish in the future.

Co-authorship network of co-authors of Weining Robieson

This figure shows the co-authorship network connecting the top 25 collaborators of Weining Robieson. A scholar is included among the top collaborators of Weining Robieson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Weining Robieson. Weining Robieson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wang, Deli, Hana Florian, Weining Robieson, et al.. (2025). Using AI‐generated digital twins to boost clinical trial efficiency in Alzheimer's disease. Alzheimer s & Dementia Translational Research & Clinical Interventions. 11(4). e70181–e70181.

Wang, Deli, Hana Florian, Weining Robieson, et al.. (2024). Assessment of AI‐generated digital twin (DT) methodology on reduction of treatment effect variance and potential clinical trial sample size saving using a Phase 2 trial dataset from patients with Alzheimer’s disease (AD). Alzheimer s & Dementia. 20(S6). 1 indexed citations

Robieson, Weining, et al.. (2024). Safety and Efficacy of Levomilnacipran Extended Release in Pediatric Patients Aged 7–17 Years with Major Depressive Disorder: Results of Two Phase 3, Randomized, Double-Blind Studies. Journal of Child and Adolescent Psychopharmacology. 34(5). 241–250. 2 indexed citations

Welsh‐Bohmer, Kathleen A., Geoffrey A. Kerchner, Shobha Dhadda, et al.. (2023). Decision making in clinical trials: Interim analyses, innovative design, and biomarkers. Alzheimer s & Dementia Translational Research & Clinical Interventions. 9(4). e12421–e12421. 1 indexed citations

Aldred, Jason, Bruno Bergmans, Camille Carroll, et al.. (2022). Safety and Efficacy of 24-Hour/Day Subcutaneous Infusion of Foslevodopa/Foscarbidopa in Advanced Parkinson’s Disease During a Phase 3 Study: 6-Month Interim Results (S16.009). Neurology. 98(18_supplement). 1 indexed citations

Liu, Ran, et al.. (2021). Modified reference based imputation and tipping point analysis in the presence of missing data due to COVID-19. Contemporary Clinical Trials. 110. 106575–106575. 3 indexed citations

Facheris, Maurizio, et al.. (2020). Safety and Tolerability in Parkinson’s Disease Patients Treated with a Continuous Subcutaneous Infusion of ABBV-951: Design of a 52-Week Phase 3 Study (4233). Neurology. 94(15_supplement). 1 indexed citations

Aldred, Jason, Norbert Kovács, Francesco E. Pontieri, et al.. (2020). Improvements in Dyskinesia with Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson’s Disease Patients in a ‘Real-World’ Study: Interim Results of the Multinational DUOGLOBE Study With up to 24 Months Follow-Up (1824). Neurology. 94(15_supplement). 1 indexed citations

Poewe, Werner, Lars Bergmann, Pavnit Kukreja, Weining Robieson, & Angelo Antonini. (2019). Levodopa-Carbidopa Intestinal Gel Monotherapy: GLORIA Registry Demographics, Efficacy, and Safety. Journal of Parkinson s Disease. 9(3). 531–541. 32 indexed citations

10.

Fernandez, Hubert H., James T. Boyd, Victor S.C. Fung, et al.. (2018). Long‐term safety and efficacy of levodopa‐carbidopa intestinal gel in advanced Parkinson's disease. Movement Disorders. 33(6). 928–936. 69 indexed citations

11.

Florian, Hana, Andreas Meier, Serge Gauthier, et al.. (2016). Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer’s Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study. Journal of Alzheimer s Disease. 51(4). 1237–1247. 31 indexed citations

12.

Murata, Miho, Masahito Mihara, Kazuko Hasegawa, et al.. (2016). Efficacy and safety of levodopa–carbidopa intestinal gel from a study in Japanese, Taiwanese, and Korean advanced Parkinson’s disease patients. npj Parkinson s Disease. 2(1). 16020–16020. 13 indexed citations

13.

Gault, Laura M., Robert Lenz, Craig Ritchie, et al.. (2016). ABT-126 monotherapy in mild-to-moderate Alzheimer’s dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension. Alzheimer s Research & Therapy. 8(1). 44–44. 33 indexed citations

14.

Waring, Jeffrey F., Qi Tang, Weining Robieson, et al.. (2015). APOE-ɛ4 Carrier Status and Donepezil Response in Patients with Alzheimer’s Disease. Journal of Alzheimer s Disease. 47(1). 137–148. 26 indexed citations

15.

Epstein, Michael, David H. Johnson, Robert H. Hawes, et al.. (2014). Gastrointestinal Safety of the Levodopa-Carbidopa Intestinal Gel Delivery System in Treating Advanced Parkinson’s Patients (P7.085). Neurology. 82(10_supplement). 2 indexed citations

16.

Bain, Earle, Weining Robieson, Yili Pritchett, et al.. (2012). A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of α4β2 Agonist ABT-894 in Adults with ADHD. Neuropsychopharmacology. 38(3). 405–413. 46 indexed citations

17.

Wilens, Timothy E., Laura M. Gault, Ann Childress, et al.. (2010). Safety and Efficacy of ABT-089 in Pediatric Attention-Deficit/Hyperactivity Disorder: Results from Two Randomized Placebo-Controlled Clinical Trials. Journal of the American Academy of Child & Adolescent Psychiatry. 50(1). 73–84.e1. 32 indexed citations

18.

Lenz, Robert, et al.. (2009). Divalproex Sodium in Children with Partial Seizures: 12-Month Safety Study. Pediatric Neurology. 41(2). 101–110. 2 indexed citations

19.

Apostol, George, Roger Cady, Genevieve Laforet, et al.. (2008). Divalproex Extended‐Release in Adolescent Migraine Prophylaxis: Results of a Randomized, Double‐Blind, Placebo‐Controlled Study. Headache The Journal of Head and Face Pain. 48(7). 1012–1025. 43 indexed citations

20.

Apostol, George, Ann Pakalnis, Genevieve Laforet, et al.. (2008). Safety and Tolerability of Divalproex Sodium Extended‐Release in the Prophylaxis of Migraine Headaches: Results of an Open‐Label Extension Trial in Adolescents. Headache The Journal of Head and Face Pain. 49(1). 36–44. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact